https://www.selleckchem.com/pr....oducts/gc376-sodium.
s in the future. The initiation of enzyme-replacement therapyprior to the occurrence of substantial and irreversible organ damage in patients with Fabry disease is of critical importance. The Fabry Outcome Survey is an international disease registry of patients with a confirmed diagnosis of Fabry disease. In this study, data from the Fabry Outcome Survey were used for the assessment of the risks for cardiovascular and renal events in patients who received agalsidase alfa treatment. Eligible patients were males and females aged ≥18